Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1793 results
August 2016
-
Media ReleaseNovartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancerDesignation underscores the continuing unmet need of the HR+/HER2- advanced breast cancer population and the potential of LEE011 (ribociclib) as an effective new treatment option Results…
-
Media ReleaseAlcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucomaUS Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma The CyPass Micro-Stent is designed to…
July 2016
-
In The NewsNovartis Access perspectives: How new business models can help fight chronic diseasesAn editorial by Harald Nusser, Head Novartis Access & Malaria Initiative, in DEVEX
-
Reigniting a passion for science
How two years in a Novartis lab changed Johnny Castillo’s life.
-
Media ReleaseNovartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospectsQ2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (…
-
Media ReleaseNovartis réalise un 2ème trimestre solide, malgré l'impact sur le trimestre du générique de Gleevec aux US; nouvelles positives importantes de l'innovation renforcent les perspectives de croissanceChiffre d'affaires net du T2 stable (0% tcc[1]), les produits de croissance[2] ayant compensé l'impact du générique de Gleevec Gilenya (USD 811 millions, +17% tcc) a continué de croître à un taux…
-
Media ReleaseNovartis erzielt im 2. Quartal solide Ergebnisse trotz US-Generikakonkurrenz für Gleevec im gesamten Quartal; wichtige positive Neuigkeiten zu Innovationen stärken zukünftige WachstumsperspektivenDer Nettoumsatz bleibt im zweiten Quartal unverändert (0% kWk[1]), da die Wachstumsprodukte[2] die Einbussen durch Generikakonkurrenz für Gleevec kompensieren Gilenya (USD 811 Millionen, +17%…
-
Featured NewsBeyond the pill: precision medicine in practice
Learn how we are shifting from making the patient fit the treatment to making the treatment fit the patient.
-
Media ReleaseAlcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopiaPresbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.[1] Dailies Total1® Multifocal contact lenses provide a seamless visual experience…
-
Media ReleaseSandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseasesCommittee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product …
-
Media ReleaseNew data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator productThe EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the…
-
In The NewsNovartis Access perspectives: Kenya's New Health Care BattleAn opinion piece by Dr. Samuel Mwenda published in US News & World Report
Pagination
- ‹ Previous page
- 1
- …
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- …
- 150
- › Next page